Navigation Links
Watson Confirms District Court Ruling in Generic Fentora® Patent Suit
Date:3/25/2011

MORRISTOWN, N.J., March 25, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), today confirmed that the United States District Court for the District of Delaware has ruled that Watson's generic version of Fentora® (fentanyl buccal tablets C-II) infringes United States Patent No. 6,264,981 (the '981 Patent).  The Company said that it was reviewing the court's decision and would evaluate all available options, including an appeal.

Watson's Abbreviated New Drug Application ("ANDA") for its generic version of Fentora® has been approved by the FDA.  

In 2008, Cephalon sued Watson for patent infringement related to its generic version of Fentora®.  On March 11, 2011, the United States District Court for the District of Delaware ruled that Watson's product does not infringe United States Patent Nos. 6,200,604 and 6,974,590 (the '604 and '590 Patents) and that the '604 and '590 Patents are invalid.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading integrated global specialty pharmaceutical company.  The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release.  It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, ; the difficulty of predicting the timing and outcome of any appeal of the pending patent litigation; the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31,2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

Fentora® is a registered trademark of Cima Labs, Inc., a subsidiary of Cephalon, Inc..

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

CONTACTS:

Investors:
Patty Eisenhaur
Watson Pharmaceuticals, Inc.
(973) 355-8141

Media:
Charlie Mayr
Watson Pharmaceuticals, Inc.
(973) 355-8483


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cephalon Wins FENTORA Patent Suit Against Watson
2. Watson Launches Generic Famvir®
3. Heygood, Orr & Pearson: Los Angeles Court Orders Watson Pharmaceuticals to Produce Documents, Provide Depositions in Fentanyl Patch Death Lawsuit
4. Watson Announces Favorable District Court Ruling in Generic Fentora® Patent Suit
5. Watson Promotes David Buchen, R. Todd Joyce to Executive Vice President
6. Watson to Present at the Barclays 2011 Global Healthcare Conference
7. Watson to Present at the Cowen & Company 31st Annual Healthcare Conference
8. Watson to Present at the 2011 Citi Global Healthcare Conference
9. Watson Fourth Quarter 2010 Net Revenue Increases 21% to $953 Million
10. Watson Announces Favorable District Court Ruling in Generic Mucinex® Patent Suit
11. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2010 Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016  The University of ... announced today that, as part of the development ... of the first hospitals in the U.S. to start ... Muraszko , M.D., U-M,s chair of neurosurgery. ... neurosurgery. --> The BrightMatter technology from ...
(Date:2/8/2016)... CITY, Calif., Feb. 8, 2016  Aoxing Pharmaceutical Company, Inc. (NYSE ... fiscal year 2016, ended December 31, 2015, the Company achieved ... recorded in the same quarter in fiscal 2015. ... in Q2 of fiscal year 2016 was $2,068,635, or $.03 ... or $.01 per share, in the Q2 of fiscal year ...
(Date:2/8/2016)... Feb. 8, 2016 ... of the "Label-Free Detection Market by ... 2020" report to their offering. ... addition of the "Label-Free Detection Market ... to 2020" report to their offering. ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Tingley Rubber ... Canada to provide its range of unique and advantaged protective solutions to ... that will provide bilingual customer service and marketing support. A new distribution center ...
(Date:2/8/2016)... (PRWEB) , ... February 08, ... ... and security executive networking and relationship-marketing firm, announced today that nominations will ... Information Security Executive® (ISE®) West Awards. , Awards include the Information ...
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth published data from its ... 2 diabetes in the GrassrootsHealth cohort with substantially higher vitamin D levels than ... public health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is ... this country. The AutismOne 2016 Conference, which is being held May 25-29 at the ... hear elsewhere about helpful interventions and causes of chronic illness in children. , Very ...
(Date:2/7/2016)... ... February 07, 2016 , ... Dr. Todd ... to his medical and surgical expertise. Technically known as deoxycholic acid or previously ... as a non-surgical alternative for reduction of fat below the chin (aka the ...
Breaking Medicine News(10 mins):